Analysts Issue Forecasts for Prime Medicine FY2025 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for Prime Medicine in a research note issued to investors on Monday, March 10th. Chardan Capital analyst G. Livshits forecasts that the company will post earnings of ($1.25) per share for the year. Chardan Capital currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share.

Prime Medicine (NYSE:PRME) last issued its quarterly earnings results on Friday, March 7th. The company reported ($1.65) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the firm earned ($2.18) EPS.

A number of other equities research analysts have also recently commented on PRME. Citizens Jmp raised Prime Medicine to a “strong-buy” rating in a research note on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Prime Medicine in a research report on Monday, March 3rd. StockNews.com upgraded Prime Medicine to a “sell” rating in a research report on Tuesday, February 11th. JMP Securities assumed coverage on Prime Medicine in a report on Tuesday, December 10th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $12.00 price objective on shares of Prime Medicine in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.13.

Prime Medicine Stock Up 4.1 %

Shares of PRME opened at $1.79 on Thursday. The stock has a market cap of $234.78 million, a P/E ratio of -0.87 and a beta of 1.85. The business’s 50 day moving average price is $2.68 and its 200-day moving average price is $3.27. Prime Medicine has a 52 week low of $1.71 and a 52 week high of $8.27.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC lifted its position in Prime Medicine by 24.6% during the fourth quarter. ProShare Advisors LLC now owns 22,186 shares of the company’s stock valued at $65,000 after acquiring an additional 4,375 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Prime Medicine by 20.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 27,811 shares of the company’s stock valued at $81,000 after purchasing an additional 4,725 shares during the last quarter. Levin Capital Strategies L.P. boosted its position in shares of Prime Medicine by 7.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 75,000 shares of the company’s stock worth $219,000 after purchasing an additional 5,000 shares in the last quarter. PEAK6 Investments LLC grew its stake in Prime Medicine by 32.4% during the 3rd quarter. PEAK6 Investments LLC now owns 45,013 shares of the company’s stock worth $174,000 after buying an additional 11,013 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in Prime Medicine during the 4th quarter valued at about $33,000. 70.37% of the stock is currently owned by institutional investors.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.